

# Preclinical development of ITC-6146RO, a B7-H3 targeting ADC, for the Treatment of Non-Small Cell Lung Cancer

IntoCell



ONCOLOGY	Preclinical
Product Type	Antibody-Drug Conjugate
Indication	Non-Small Cell Lung Cancer (NSCLC)
Target	B7-H3
MoA(Mechanism of Action)	B7-H3 targeting Ab combined with Duocarmycin derivative, a DNA alkylating toxin, is internalized into lysosome of cancer cell. Then the toxin part is cleaved and released into the cell to disrupt cell division by alkylating DNA.
Competitiveness	<ul style="list-style-type: none"> <li>• Self-immolative OHPAS linker : highly stable in circulation and rapid release of payload in the targeted tissues.</li> <li>• Payload modification technology (PMT) : Reduces non-specific uptake in normal cells → Improved therapeutic index.</li> <li>• Site specific conjugation of drug-linker : Improved homogeneity of DAR, simplified quality control with high reproducibility.</li> </ul>
Development Stage	Preclinical
Route of Administration	Iv infusion